Aquestive Therapeutics Q2 revenue beats on Suboxone strength

Aquestive Therapeutics

11/08/2026 21:10

Overview
U.S. pharmaceutical developer's Q2 revenue rose 38% yr/yr, beating analyst expectations
Net loss widened due to one-time debt extinguishment loss

Outlook
Aquestive expects 2026 revenue of $46 mln to $50 mln
Company sees 2026 non-GAAP adjusted EBITDA loss of $35 mln to $30 mln

Result Drivers
MANUFACTURE AND SUPPLY REVENUE - Revenue growth was mainly driven by higher manufacture and supply revenue, primarily from increased Suboxone revenues
LICENSE AND ROYALTY REVENUE - Higher license and royalty revenue, mainly from Zevra, contributed to overall revenue growth
INCREASED PRODUCTION VOLUME - The company produced more doses in Q2 2026 compared to Q2 2025, supporting higher revenue

Company press release: ID:nGNXc9qqHq

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$13.82 mln
$11.42 mln (8 Analysts)
Q2 Loss Per Share
 
$0.18
 
Q2 Net Loss
 
$22.86 mln
 
Q2 Adjusted EBITDA
Beat
-$5.20 mln
-$7.95 mln (2 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $10.00, about 133.1% above its August 10 closing price of $4.29

Reuters Recommended Reads
Aug 10 - Harrow Q2 revenue slightly beats estimates
Aug 11 - Fennec Pharmaceuticals Q2 sales rise on PEDMARK demand
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)